Accounts Receivable, after Allowance for Credit Loss, Current of NovaBay Pharmaceuticals, Inc. from 31 Dec 2022 to 30 Sep 2024

Taxonomy & unit: us-gaap: USD
Description: Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary: NovaBay Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2022 to 30 Sep 2024.
NovaBay Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2024 was $704,000.
Source SEC data: View on sec.gov

Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

NovaBay Pharmaceuticals, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2024	$704,000			30 Sep 2024	10-Q	07 Nov 2024	2024	Q3
Q2 2024	$547,000			30 Jun 2024	10-Q	13 Aug 2024	2024	Q2
Q1 2024	$734,000			31 Mar 2024	10-Q	09 May 2024	2024	Q1
Q4 2023	$680,000	-$1,293,000	-66%	31 Dec 2023	10-Q	07 Nov 2024	2024	Q3
Q4 2022	$1,973,000			31 Dec 2022	10-K	26 Mar 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.